Ntavatzikos A, Spathis A, Patapis P, Machairas N, Vourli G, Peros G, Papadopoulos I, Panayiotides I, Koumarianou A. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World J Gastrointest Oncol 2019; 11(7): 551-566 [PMID: 31367274 DOI: 10.4251/wjgo.v11.i7.551]
Corresponding Author of This Article
Anastasios Ntavatzikos, MD, Research Scientist, Hematology-Oncology Unit, 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, “ATTIKON” University Hospital, Rimini 1, Haidari, Athens 12462, Greece. dmaal2@yahoo.gr
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 6 Multivariate Cox regression analysis for clinicopathological features and selected genotypes
Variable
HR
DFS 95%CI
P value
HR
OS 95%CI
P value
Stage III vs I and II
2.432
1.279-4.625
0.007
Grade III and IV vs I and II
1.715
0.951-3.091
0.073
1.860
0.982-3.525
0.057
TYMS 5’UTR groups
0.031
0.052
A
3.122
1.193-8.169
0.020
2.715
1.093-6.739
0.031
B
1
1
C
2.919
1.258-6.772
0.013
2.540
1.098-5.876
0.029
TYMS 3’UTR groups
A (without ins/LOH)
1
B (ins/LOH)
4.124
1.744-9.753
0.001
3.335
1.474-7.548
0.004
BRAF V600E mutation
4.500
1.241-16.32
0.022
Citation: Ntavatzikos A, Spathis A, Patapis P, Machairas N, Vourli G, Peros G, Papadopoulos I, Panayiotides I, Koumarianou A. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World J Gastrointest Oncol 2019; 11(7): 551-566